UK's NICE Clears Roche Drug For Use In Follicular LymphomaCapital.gr (press release)The decision confirms draft guidance issued last May and follows months of consideration by the National Institute for Health and Clinical Excellence, which has now…
Spectrum reports encouraging results from ZEVALIN studyPharmaceutical Business ReviewThe standard-dose ibritumomab tiuxetan combined with BEAM high-dose chemotherapy is safe and effective than BEAM alone as conditioning regimen for ASCT in the era of r…
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment …EON: Enhanced Online News (press release)Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, dacl…
Severe High-Density Lipoprotein Deficiency Associated With Autoantibodies …Archives of Internal MedicineOn July 2007, treatment started with 3 cycles of cyclophosphamide, hydroxyldaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (CHOP…
Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment …MarketWatch (press release)Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocreli…
ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive …MarketWatch (press release)In the era of rituximab-containing frontline regimens, it is becoming more challenging to salvage patients with ASCT in this setting, and novel ap…
Sandoz Initiates Two More Phase III Biosimilar Trials, Reinforcing Long-term …VAdvert Press Center (press release)Ameet Mallik, global head of Sandoz Biopharmaceuticals, added: “The start of these two studies represents significant progress for our…
Neutral on Biogen – Analyst BlogNASDAQOther interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments…
Neutral On BiogenDaily Markets (blog)Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen's pipeline also has candidates for other ailmen…
Neutral on BiogenZacks.comOther interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs (ABT), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments like amyotrop…